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m2 Muscarinic Acetylcholine Receptor (mAchR) Subtype Is
Present in Human Epidermal Keratinocytes In Situ and In Vitro
To the Editor:
Previously it has been demonstrated in vitro and in situ
that human keratinocytes hold the capacity for muscarinic
(m) and nicotinic signal transduction (Grando et al, 1995;
Grando, 1997; Grando and Horton, 1997). Furthermore,
these cells can synthesize and degrade acetylcholine
(Grando et al, 1993). To date, the presence of the classical
m1, m3, m4, and m5 muscarinic acetylcholine receptor
(mAchR) subtypes has been extensively documented in the
human epidermis (Ndoye et al, 1998). Moreover, these ep-
idermal receptors have been characterized expressing high
affinity and high densities (Grando et al, 1995).
Interestingly, the presence of the m2 AchR has been rec-
ognized on melanocytes in the human epidermis and
on gingival keratinocytes while expression has never been
demonstrated in keratinocytes in the epidermal compartment
(Buchli et al, 2001; Arrendondo et al, 2003). The m2 AchR
subtype inhibits adenylyl cyclase activity by releasing the a
subunit of the Gi protein family thus downregulating the
cAMP response. After binding to the Gi bg subunits
phospholipase C is activated leading to the formation of
IP3 and DAG followed by an increase of intracellular calcium
and activation of protein kinase C (PKC) (Nathanson, 2000).
Calcium is central in control of keratinocyte growth and dif-
ferentiation. Furthermore, the m2 AchR can activate the
mitogen activated kinase (MAPK) pathway through Gi bg ac-
tivation of IP3 kinase with subsequent involvement of Ras
and Raf (Lopez-Ilasaca et al, 1997). Moreover, the m2 re-
ceptor activates GTPase activator protein via Gia protein for
Rap1, which can in turn antagonize Ras action. In addition
the m2 AchR is generally considered to block b-adrenergic
receptor-mediated action. Since epidermal keratinocytes
hold all of the above signals, it was tempting to readdress
the presence of this m receptor in these cells. Therefore, we
first followed possible immunoreactivity using 3 mm punch
biopsies of full thickness skin from the inner forearm of 3
healthy volunteers taken under local anesthesia after written
informed consent. This study has been approved by the
ethics commitee of the University of Bradford. The study was
conducted according to the Declaration of Helsinki Princi-
ples. Moreover, we established primary keratinocyte cell cul-
tures in MCDB 153 medium from epidermal suction blister
tissue using the method of Wille et al (1984). Differentiation
was induced by removal of growth factors and by increasing
the calcium concentration in the medium (Wille et al, 1984).
Acetone fixed cryosections (7 mm) of full skin and keratin-
ocytes established on chamber slides (Nalge Nunc Inter-
national, Naperville, Illinois) were immunostained with a
polyclonal rabbit IgG fraction directed against residues
457–466 of the carboxyl terminal of human m2 AchR (R&D
Antibodies, Benicia, California) after prior titration in the di-
lution 1:5000 for in situ expression and 1:500 for keratin-
ocytes followed by fluorescence labelling with tetramethyl
rhodamine isothiocyanate (TRITC) conjugated polyclonal anti-
rabbit IgG antibody (Abcam, Cambridge, UK) at the dilution
1:100. The presence of a strong immunoreactivity of m2 AchR
throughout the entire epidermis is shown in Fig 1A. The
specificity was confirmed using a rabbit m2 AchR blocking
peptide with the sequence Cys–His–Tyr–Lys–Asn–Ile–Gly–
Ala–Thr–Arg (R&D Antibodies) (Fig 1A). Under in vitro condi-
tions a strong perinuclear and a weaker cytosolic staining
occurs in undifferentiated keratinocytes (Fig 1B). The protein
expression is stronger in differentiated cells (Fig 1C). Nuclear
staining was specific after using 40,6-diamino-2-phenylindole
(DAPI) and m2 AchR in overlay in the presence and absence
of the blocking peptide. (Fig 1B, C). Hence the m2 AchR
seems to be expressed in the nucleus. The specificity of the
protein expression was confirmed by immunoblotting using
the same m2 AchR as described above in the dilution 1:8
together with the above m2 AchR blocking peptide. The re-
sults show the presence of a 65 kDa band (Fig 2A) which is in
agreement with the size of the m2 AchR as established earlier
in gingival keratinocytes and human skin fibroblasts (Buchli
et al, 1999, 2001; Arrendondo et al, 2003). After blocking the
65 kDa band was absent (Fig 2A). In order to confirm tran-
scription of m2 AchR and to strengthen the above results, we
followed the expression of mRNA for m2 AchR by RT-PCR.
Total RNA was isolated from cultured epidermal primary ker-
atinocytes using TRI REAGENT (Sigma, Dorset, UK) following
manufacturer’s instructions. Samples were treated with
DNAse to eliminate possible contamination.
cDNA was synthesized using the reverse transcription
system (Promega, Southampton, UK) following the protocol
as published in detail (Hasse et al, 2004). The primer pair
(forward: 50 ACAAGAAGGAGCCTGTTGCC 30 and reverse:
50 CAATCTTGCGGGCTACAATAT 30) was designed using the
mRNA sequence of human m2 AchR (GenBank accession
number: NM_000739).
The results show the presence of a 438 bp mRNA
(Fig 2B) that corresponds to the expected size of the m2 AchR
as documented in epidermal melanocytes (Buchli et al, 2001).
In summary, we have provided the first evidence for the
presence of m2 AchR in human epidermal keratinocytes
Abbreviations: AchR, acetylcholine receptor; m, muscarinic; PKC,
protein kinase C; MAPK, mitogen activated kinase; DAPI, 40,6-
diamino-2-phenylindole
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in situ and in vitro. Therefore we can conclude that the
human epidermis contains all five m receptor subtypes. The
specific role for m2 AchR function in the human epidermis
needs further investigation.
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Figure2
Evidence for the presence of muscarinic 2 acetylcholine receptor
(AchR) expression on human epidermal keratinocytes using
immunoblotting and RT-PCR. (A) Western blotting in the presence
and absence of m2 AchR blocking peptide confirms the expression of
the receptor with a MW of 65 kDa. (B) RT-PCR yields mRNA with a 438
bp product corresponding to the established size of m2 AchR.
Figure 1
In situ and in vitro immunostaining confirms muscarinic 2 acetyl-
choline receptor (AchR) expression in human epidermal keratin-
ocytes. (A) In situ expression of m2 AchR is seen throughout the entire
epidermis whereas the protein is absent in the presence of the specific
blocking peptide. Magnification  200 (20 mm). (B) In vitro expression
of m2 AchR in undifferentiated keratinocytes showing a more pro-
nounced perinuclear with some granular staining in the cytosol and in
the nucleus. The overlay of DAPI and m2 AchR in the presence and
absence of blocking peptide indicates a weak expression of m2 AchR
in the nucleus (inset). Magnification  400 (400 mm). (C) In vitro m2
AchR expression in differentiated keratinocytes is more diffuse but
much stronger compared with undifferentiated keratinocytes. The inset
shows also a stronger nuclear staining compared with undifferentiated
cells that is absent after blocking. Magnification  400.
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